Global Oncology Academy

What to Know About ESR1 Mutations in HR+/HER2- Metastatic Breast Cancer

ReachMD Healthcare Image
RestartResume

Find out how ESR1 mutations can impact our approach to treating patients with HR+/HER2- metastatic breast cancer in this brief program.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    ESR1 mutations are frequently acquired during aromatase inhibitor treatment for HR+/HER2- metastatic breast cancer, making liquid biopsy monitoring vital to identify endocrine resistance. Learn more about this acquired mutation and how it can impact treatment with Dr. Mariya Rozenblit, Assistant Professor of Medicine in the Section of Medical Oncology at the Yale School of Medicine.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free